Hikma Pharmaceuticals Plc 9.6% potential upside indicated by Barclays

Hikma Pharmaceuticals Plc with ticker (LON:HIK) now has a potential upside of 9.6% according to Barclays.



Barclays set a target price of 2,000 GBX for the company, which when compared to the Hikma Pharmaceuticals Plc share price of 1,825 GBX at opening today (12/04/2024) indicates a potential upside of 9.6%. Trading has ranged between 1,711 (52 week low) and 2,222 (52 week high) with an average of 435,209 shares exchanging hands daily. The market capitalisation at the time of writing is £4,109,736,261.

Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio. Its subsidiaries include Al Jazeera Pharmaceutical Industry S.A.R.L, Hikma Pharma Algeria S.A.R.L. and others.